Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation and immunology conditions. Its wholly owned lead candidate, PIPE-791, is an inhibitor of the lysophosphatidic acid 1 receptor being studied for idiopathic… From the company’s description.
In fiscal 2025, Contineum Therapeutics, Inc. reported a net loss of $59.98M. Operations used $55.31M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Contineum Therapeutics, Inc. does
In the company’s own words
Contineum Therapeutics, Inc. (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation and immunology conditions. Its wholly owned lead candidate, PIPE-791, is an inhibitor of the lysophosphatidic acid 1 receptor being studied for idiopathic pulmonary fibrosis and chronic pain, including osteoarthritic and low back pain. The company began a Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis in December 2025 and completed enrollment in an exploratory Phase 1b chronic-pain trial in 2025. Its second clinical-stage candidate, PIPE-307, is a selective muscarinic type 1 receptor inhibitor being developed for depression and relapsing-remitting multiple sclerosis. Contineum has partnered with Johnson & Johnson for PIPE-307’s development and potential commercialization; the partner conducts development at its discretion. The company retains worldwide rights to its LPA1 receptor programs and discovery portfolio and also conducts preclinical and discovery-stage research into other conditions. Its portfolio includes programs at clinical and earlier research stages, rather than reportable business segments.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1855175
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Contineum Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Contineum Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Contineum Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Contineum Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Contineum Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”